急性COVID-19心血管综合征的描述与拟议管理
本文综述急性COVID-19心血管综合征的流行病学、发病机制、诊断与治疗,该综合征常表现为无阻塞性冠脉病的急性心肌损伤伴心肌病、室性心律失常及血流动力学不稳。病因疑与心肌炎、微血管损伤、细胞因子介导损伤或应激性心肌病相关。文章提出兼顾患者风险与医护暴露的监测、诊断和管理策略。
要点
- 住院COVID-19患者中相当少数出现急性心血管综合征,常无阻塞性冠脉病。
- 疑因包括心肌炎、微血管损伤、细胞因子损伤或应激性心肌病。
- 管理需重症、感染与心内科多学科团队,平衡医护暴露与早期识别。
核心结论
- 急性COVID-19心血管综合征常表现为无阻塞性冠脉病的急性心肌损伤伴心肌病、室性心律失常和血流动力学不稳。
- 病因尚不确定,疑与心肌炎、微血管损伤、系统性细胞因子介导损伤或应激相关心肌病有关。
- 管理应多学科协作,并平衡医护暴露风险与早期识别干预的获益。
研究设计与样本
- 本文为综述,汇总急性COVID-19心血管综合征的流行病学、发病机制、诊断与治疗数据。
主要发现
- 住院患者中相当少数发生急性COVID-19心血管综合征,临床表现多样。
- 严重急性呼吸综合征冠状病毒2可能直接复制于心肌细胞和周细胞导致病毒性心肌炎,但组织学未证实。
- 系统性升高的细胞因子具有心脏毒性,可能导致严重心肌损伤。
- 既往严重急性呼吸综合征冠状病毒1的经验加速了抗病毒药、白介素-6抑制剂和恢复期血清等疗法的评估。
临床怎么用
- 管理急性COVID-19心血管综合征应组建包括重症、感染和心内科的多学科团队。
- 优先平衡避免不改变临床管理的检测以减少医护暴露,与早期识别综合征以在最佳时机干预。
- 基于现有数据提出兼顾患者风险、医护暴露与临床结局改善的监测、诊断和管理策略。
局限性
- 心肌内直接病毒复制导致心肌炎仅属推测,组织学尚未证实。
- 急性COVID-19心血管综合征的病因仍不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (COVID-19) is a rapidly expanding global pandemic caused by severe acute respiratory syndrome coronavirus 2, resulting in significant morbidity and mortality. A substantial minority of patients hospitalized develop an acute COVID-19 cardiovascular syndrome, which can manifest with a variety of clinical presentations but often presents as an acute cardiac injury with cardiomyopathy, ventricular arrhythmias, and hemodynamic instability in the absence of obstructive coronary artery disease. The cause of this injury is uncertain but is suspected to be related to myocarditis, microvascular injury, systemic cytokine-mediated injury, or stress-related cardiomyopathy. Although histologically unproven, severe acute respiratory syndrome coronavirus 2 has the potential to directly replicate within cardiomyocytes and pericytes, leading to viral myocarditis. Systemically elevated cytokines are also known to be cardiotoxic and have the potential to result in profound myocardial injury. Prior experience with severe acute respiratory syndrome coronavirus 1 has helped expedite the evaluation of several promising therapies, including antiviral agents, interleukin-6 inhibitors, and convalescent serum. Management of acute COVID-19 cardiovascular syndrome should involve a multidisciplinary team including intensive care specialists, infectious disease specialists, and cardiologists. Priorities for managing acute COVID-19 cardiovascular syndrome include balancing the goals of minimizing healthcare staff exposure for testing that will not change clinical management with early recognition of the syndrome at a time point at which intervention may be most effective. This article aims to review the best available data on acute COVID-19 cardiovascular syndrome epidemiology, pathogenesis, diagnosis, and treatment. From these data, we propose a surveillance, diagnostic, and management strategy that balances potential patient risks and healthcare staff exposure with improvement in meaningful clinical outcomes.
引用
- Hendren NS, Drazner MH, Bozkurt B, et al. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020. PMID: 32297796. doi:10.1161/CIRCULATIONAHA.120.047349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。